CRISPR and Antisense RNA Technology: Exploiting Nature’s Tool to Restrain Virulence in Tenacious Pathogens

Ashwath, Priyanka; Somanath, Disha; Akhila, Dharnappa Sannejal

doi:10.1007/s12033-022-00539-4

Cited by 2 publications

(1 citation statement)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NADs include cDNA (translation function protein) [16], mRNA (translation function protein) [17] and noncoding RNAs [18]. Noncoding RNAs include ASO (antisense oligonucleic acid, binding target genes to regulate gene expression) [19], ribozymes (specific splicing RNA) [20], siRNA (RNA-induced silencing complexes (RISCs) degrade RNA) [21], miRNA (RISCs degrade RNA) [22], aptamers (specific binding to target molecules regulates gene expression) [23].…”

Section: Classifications and Injection Schemes Of Nads In Gene Therap...mentioning

confidence: 99%

Nanotechnology Lighting the Way for Gene Therapy in Ophthalmopathy: From Opportunities toward Applications

et al. 2023

View full text Add to dashboard Cite

Hereditary ophthalmopathy is a well-described threat to human visual health affecting millions of people. Gene therapy for ophthalmopathy has received widespread attention with the increasing understanding of pathogenic genes. Effective and safe delivery of accurate nucleic acid drugs (NADs) is the core of gene therapy. Efficient nanodelivery and nanomodification technologies, appropriate targeted genes, and the choice of drug injection methods are the guiding lights of gene therapy. Compared with traditional drugs, NADs can specifically change the expression of specific genes or restore the normal function of mutant genes. Nanodelivery carriers can improve targeting and nanomodification can improve the stability of NADs. Therefore, NADs, which can fundamentally solve pathogeny, hold great promise in the treatment of ophthalmopathy. This paper reviews the limitations of ocular disease treatment, discusses the classification of NADs in ophthalmology, reveals the delivery strategies of NADs to improve bioavailability, targeting, and stability, and summarizes the mechanisms of NADs in ophthalmopathy.

show abstract

Section: Classifications and Injection Schemes Of Nads In Gene Therap...mentioning

confidence: 99%

Nanotechnology Lighting the Way for Gene Therapy in Ophthalmopathy: From Opportunities toward Applications

et al. 2023

View full text Add to dashboard Cite

show abstract

Cross-Kingdom RNA Transport Based on Extracellular Vesicles Provides Innovative Tools for Plant Protection

Zhao,

Zhou,

et al. 2024

Plants

View full text Add to dashboard Cite

RNA interference (RNAi) shows great potential in plant defense against pathogens through RNA-mediated sequence-specific gene silencing. Among RNAi-based plant protection strategies, spray-induced gene silencing (SIGS) is considered a more promising approach because it utilizes the transfer of exogenous RNA between plants and microbes to silence target pathogen genes. The application of nanovesicles significantly enhances RNA stability and delivery efficiency, thereby improving the effectiveness of SIGS and further enhancing plant resistance to diseases and pathogens. This review explores the role of RNAi in plant protection, focusing on the cross-kingdom transport of small RNAs (sRNAs) via extracellular vesicles. It also explores the potential of nanotechnology to further optimize RNA-based plant protection, offering innovative tools and methods in modern plant biotechnology.

show abstract

CRISPR and Antisense RNA Technology: Exploiting Nature’s Tool to Restrain Virulence in Tenacious Pathogens

Cited by 2 publications

References 80 publications

Nanotechnology Lighting the Way for Gene Therapy in Ophthalmopathy: From Opportunities toward Applications

Nanotechnology Lighting the Way for Gene Therapy in Ophthalmopathy: From Opportunities toward Applications

Cross-Kingdom RNA Transport Based on Extracellular Vesicles Provides Innovative Tools for Plant Protection

Contact Info

Product

Resources

About